Conjugation News and Research

RSS

New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses

Researchers at Georgia Tech and the University of Wisconsin have created a broad-spectrum vaccine capable of defending against various SARS-CoV-2 variants and related bat coronaviruses.

17 Apr 2024

Global health boost as new vaccine SKYTyphoid gains WHO prequalification

SK bioscience and the International Vaccine Institute (IVI) announced today that the typhoid conjugate vaccine developed by SK bioscience with technology transfer from IVI has achieved the World Health Organization prequalification (PQ), which paves the way for public procurement of the vaccine by UN organizations and gives a boost to the global TCV supply.

23 Feb 2024

Simple technique boosts antibody delivery for treating brain diseases

The blood-brain barrier blocks the entry of antibodies into the brain. This limits the potential use of antibody therapeutics to treat brain diseases, such as brain tumors.

3 Jan 2024

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development

Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition of new evolocumab (Repatha), ipilimumab (Yervoy), and secukinumab (Cosentyx) antibodies.

From Bio-Rad Laboratories 6 Oct 2023

Study highlights a promising therapy to mitigate spaceflight-induced bone loss

A new study published in a Nature Partner Journal, npj Microgravity, finds an engineered compound given to mice aboard the International Space Station (ISS) largely prevented the bone loss associated with time spent in space.

18 Sep 2023

Unlocking ACE2: The enzyme that links COVID-19, heart disease, and diabetes

A recent study in the Journal of Biomedical Science examines the critical role of ACE2, an enzyme involved in blood volume and electrolyte balance, in chronic diseases like cardiovascular conditions, diabetes, and COVID-19. The research suggests that ACE2 could serve as both a disease severity biomarker and a therapeutic target.

28 Aug 2023

Current and future strategies for vaccinating against invasive pneumococcal disease

Researchers reviewed the immune mechanisms employed by existing vaccines for invasive pneumococcal disease.

23 Aug 2023

Study finds α5 integrin as a potential therapeutic target in amyotrophic lateral sclerosis

Researchers examined the therapeutic effects of targeting integrins for treating Amyotrophic lateral sclerosis (ALS).

3 Aug 2023

Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d'Hebron Institute of Oncology's (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), 2-6 June in Chicago, USA.

4 Jun 2023

Synthetic delivery vector STxB induces mucosal immunity against viral antigens

Research describes the development of a synthetic delivery vector called STxB for mucosal vaccination. It induces mucosal immunity, including resident memory CD8+ T cells and IgA antibodies, against antigens derived from mucosal viruses when administered intranasally in mice.

21 May 2023

The safety and efficacy of FINLAY-FR-2/1A, a new protein-based COVID-19 vaccine

Research paper reports the results of a phase 3 clinical trial evaluating the efficacy and safety of the FINLAY-FR-2 and FINLAY-FR-1A vaccines in Iranian adults.

7 May 2023

Super-polymers are used by gut bacteria to fend off antibiotics

The discovery shows why it can be so difficult to tackle drug-resistant bacteria, but does provide a possible avenue for tackling the problem.

21 Apr 2023

Study finds mobile antibiotic resistance genes in some probiotic bacteria, raising concerns for public health

Researchers examine antibiotic resistance genes and their mobility in Bifidobacteriales and Lactobacillales species.

11 Apr 2023

Novel therapeutic eradicates gastric cancer in treated mice

A novel cancer therapeutic, combining antibody fragments with molecularly engineered nanoparticles, permanently eradicated gastric cancer in treated mice, a multi-institutional team of researchers found.

17 Mar 2023

New funding to accelerate development of potential anti-cancer compound into the clinic

For the past few decades, Dr. Iwao Ojima has been working in his Stony Brook University Department of Chemistry Laboratory and through the Institute of Chemical Biology & Drug Discovery (ICB&DD) to develop next-generation anti-cancer agents.

28 Feb 2023

Simple method increases the efficacy of T cell therapy by cytokine conjugation

The recent years have seen a wave of adoptive cell therapies (ACTs), a type of immunotherapy in which T cells (T cell transfer therapy) and other immune cells are obtained from patients, activated and multiplied outside the body, and infused in larger numbers back into the blood circulation to help fight cancers.

11 Jan 2023

Researchers review bacteriophage treatment

Researchers presented an overview of bacteriophage treatment, including mechanisms, types, design and applications of bacteriophage therapy.

10 Jan 2023

COVID-19 vaccine potency and breadth improved by nanoparticle-conjugated adjuvants

In a recent study posted to bioRxiv*, researchers designed a nanoparticle (NP)-conjugated toll-like receptor 9 (TLR9) agonist to improve the adjuvanticity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.

8 Jan 2023

Horizontal gene transfer from mother to infant influences gut microbiome assembly, neurodevelopment, and immune maturation in infants

Researchers used a multi-omics approach to profile the gut microbiomes and metabolomes of mothers and infants to determine the vertical and horizontal transmission of bacterial species and strains as well as individual genes and understand the dynamics of the gut microbiome assembly that shape the development of the infant before and after birth.

29 Dec 2022

Applied Cells Inc. and GenScript enter strategic collaboration to deliver combined solutions for cell therapy development

November 18th, 2022. Today, Applied Cells Inc. and GenScript USA Incorporated announced their strategic collaboration to deliver combined cell isolation solutions for cell therapy drug development worldwide. Under this collaboration, GenScript will develop and supply its proprietary research and cGMP grade CytoSinct™ reagents for use in developing CAR-T and other Cell Therapy products on the Applied Cells MARS® Platform.

25 Nov 2022